## Diagnosis: Visceral Leishmaniasis (Kala-azar) ### Clinical Recognition **Key Point:** The combination of prolonged fever (>2 weeks), hepatosplenomegaly, pancytopenia, and bone marrow amastigotes in an endemic region (Bihar) is pathognomonic for kala-azar caused by *Leishmania donovani*. **High-Yield:** Amastigotes are intracellular, oval, 2–3 μm parasites found within macrophages, monocytes, and dendritic cells. They lack a free flagellum (unlike promastigotes). ### Current First-Line Treatment in India **Clinical Pearl:** The National Vector Borne Disease Control Programme (NVBDCP) of India and WHO guidelines have updated the first-line treatment for visceral leishmaniasis in the Indian subcontinent. **Miltefosine** (oral) is now the recommended first-line agent in India, replacing sodium stibogluconate (SSG) due to widespread SSG resistance in Bihar and Uttar Pradesh (treatment failure rates of 60–65% in some endemic districts of Bihar). | Drug | Status in India | Dosing | Duration | Notes | |------|----------------|--------|----------|-------| | **Miltefosine** | **1st-line (current)** | 2.5 mg/kg/day PO | 28 days | Oral convenience; teratogenic; avoid in pregnancy | | Amphotericin B (liposomal) | 1st-line alternative | Single dose 10 mg/kg IV | 1 day | Preferred in pregnancy; high cost | | Amphotericin B deoxycholate | 2nd-line | 1 mg/kg/day IV | 15–20 days | Nephrotoxicity risk | | Sodium stibogluconate | No longer 1st-line in India | 20 mg/kg/day IV/IM | 28 days | High resistance in Bihar; still used in Africa | | Pentamidine | Rarely used | 4 mg/kg/day IM | 15 days | Hypoglycemia risk; reserved for specific resistance | ### Why Miltefosine (Option C) is Correct 1. **Endemic region (Bihar):** SSG resistance in Bihar is now 60–65% in some areas, making it unsuitable as first-line therapy. Indian national guidelines (NVBDCP) and WHO recommend miltefosine as first-line oral therapy for kala-azar in India. 2. **Oral administration:** Particularly advantageous in a cachectic patient with pancytopenia where IV access and monitoring may be challenging. 3. **Standard dosing:** 2.5 mg/kg/day orally for 28 days; cure rates >90% in drug-sensitive strains. 4. **Uncomplicated kala-azar:** No contraindications mentioned (patient is male, so teratogenicity is not a concern). ### Why SSG (Option D) is Incorrect for This Patient - Bihar is a high SSG-resistance zone; treatment failure rates are unacceptably high. - Indian national guidelines have moved away from SSG as first-line in the Indian subcontinent. - SSG remains first-line in East Africa and other regions where resistance is not prevalent. ### When to Use Amphotericin B - Miltefosine treatment failure or relapse - Pregnancy (liposomal amphotericin B preferred) - Severe/complicated kala-azar with organ dysfunction **Mnemonic — Kala-azar in India: "Miltefosine First (Oral), Ampho Second, SSG Retired"** — reflects current Indian guidelines due to SSG resistance in Bihar. *(Reference: WHO Technical Report on Leishmaniasis 2022; NVBDCP India Guidelines; Harrison's Principles of Internal Medicine, 21st ed.)*
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.